Published in J Pharmacol Exp Ther on January 14, 2004
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology (2011) 1.97
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Intranasal treatment of central nervous system dysfunction in humans. Pharm Res (2012) 1.07
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One (2012) 0.98
Hormones in the naso-oropharynx: endocrine modulation of taste and smell. Trends Endocrinol Metab (2009) 0.96
Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol (2010) 0.96
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) (2012) 0.93
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev (2011) 0.91
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement (2014) 0.88
Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res (2013) 0.86
Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab (2011) 0.86
Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. AAPS J (2015) 0.85
Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin. J Pharmacol Exp Ther (2014) 0.83
Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides (2012) 0.81
Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine. Int J Endocrinol (2015) 0.80
Agile delivery of protein therapeutics to CNS. J Control Release (2014) 0.79
Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One (2012) 0.79
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. AAPS J (2015) 0.79
Hindbrain oxytocin receptors contribute to the effects of circulating oxytocin on food intake in male rats. Endocrinology (2014) 0.79
Antidiabetic treatment, stroke severity and outcome. World J Diabetes (2014) 0.78
Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System. Front Endocrinol (Lausanne) (2014) 0.78
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice. J Neurol Neurosurg (2015) 0.78
Validation of anatomical models to study aerosol deposition in human nasal cavities. Pharm Res (2013) 0.77
Effects of chemosignals from sad tears and postprandial plasma on appetite and food intake in humans. PLoS One (2012) 0.77
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. Physiol Behav (2015) 0.77
Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery. Peptides (2016) 0.76
Smell and Taste Dysfunction Is Associated with Higher Serum Total Cholesterol Concentrations in Chinese Adults. J Nutr (2017) 0.76
Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil. ScientificWorldJournal (2012) 0.75
Intranasal glucagon: a promising approach for treatment of severe hypoglycemia. J Diabetes Sci Technol (2014) 0.75
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron (2009) 4.18
Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell (2010) 3.71
VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet (2004) 3.60
White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis. Cell Metab (2011) 2.68
Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci (2005) 1.92
Homer proteins regulate sensitivity to cocaine. Neuron (2004) 1.83
Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo. Neuron (2011) 1.78
Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci (2004) 1.66
Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther (2009) 1.66
The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci U S A (2007) 1.57
NMDA receptors inhibit synapse unsilencing during brain development. Proc Natl Acad Sci U S A (2008) 1.52
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A (2006) 1.51
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods (2002) 1.42
Gene therapy for spinal cord injury and disease. J Spinal Cord Med (2002) 1.41
Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 1.40
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain (2008) 1.36
Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain. Nat Med (2006) 1.35
Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides (2007) 1.35
Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward. Science (2006) 1.35
Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci (2003) 1.32
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther (2008) 1.31
Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol (2002) 1.30
Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med (2009) 1.28
Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.26
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab (2006) 1.26
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Long-term follow-up after gene therapy for canavan disease. Sci Transl Med (2012) 1.22
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther (2004) 1.16
Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem (2007) 1.14
Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo. J Neurosci (2008) 1.12
Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res (2002) 1.09
Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther (2005) 1.08
Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther (2003) 1.08
Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. J Neurosci (2005) 1.08
Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol (2004) 1.07
Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J (2003) 1.06
Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener (2007) 1.06
Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine. Brain Res (2003) 1.04
What is the brain-cancer connection? Annu Rev Neurosci (2012) 1.04
Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging rats. Proc Natl Acad Sci U S A (2006) 1.03
ATF3 enhances c-Jun-mediated neurite sprouting. Brain Res Mol Brain Res (2003) 1.03
Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. Mol Ther (2002) 1.02
Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab (2008) 1.01
Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J Pharmacol Exp Ther (2002) 1.00
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis (2004) 1.00
Local dopamine production in the dorsal striatum restores goal-directed behavior in dopamine-deficient mice. Behav Neurosci (2006) 0.97
Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia (2006) 0.97
A novel role of circadian transcription factor DBP in hippocampal plasticity. Mol Cell Neurosci (2005) 0.97
Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol (2010) 0.96
Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis (2012) 0.94
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol (2003) 0.94
Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol Psychiatry (2003) 0.93
Paradoxical facilitatory effect of low-dose alcohol consumption on memory mediated by NMDA receptors. J Neurosci (2007) 0.92
Over expression of ATF-3 protects rat hippocampal neurons from in vivo injection of kainic acid. Brain Res Mol Brain Res (2004) 0.92
Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier. Biochem Biophys Res Commun (2004) 0.92
Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport (2003) 0.92
Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis (2012) 0.92
Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J Neurosci (2009) 0.91
Molecular investigation of TBP allele length: a SCA17 cellular model and population study. Neurobiol Dis (2003) 0.90
Localized disruption of Narp in medial prefrontal cortex blocks reinforcer devaluation performance. Learn Mem (2010) 0.90
Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. PLoS One (2013) 0.90
Network modulation following sham surgery in Parkinson's disease. J Clin Invest (2014) 0.89
Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Neuron (2004) 0.89
Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology (2006) 0.88
NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus (2008) 0.88
Gene therapy in epilepsy. Epilepsia (2008) 0.87
Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice. Eur Neuropsychopharmacol (2009) 0.87
Viral mediated neuropeptide Y expression in the rat paraventricular nucleus results in obesity. Obesity (Silver Spring) (2007) 0.87
A role for dopamine in feeding responses produced by orexigenic agents. Brain Res (2004) 0.86
Environmental enrichment exerts sex-specific effects on emotionality in C57BL/6J mice. Behav Brain Res (2010) 0.86
Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol (2008) 0.86
Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B. J Neurochem (2009) 0.86
Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size. Stroke (2013) 0.86
A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. J Pharmacol Exp Ther (2010) 0.86
Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia. J Neurochem (2007) 0.85
Permeability of the mouse blood-brain barrier to murine interleukin-2: predominance of a saturable efflux system. Brain Behav Immun (2004) 0.85
Knockdown and overexpression of NR1 modulates NMDA receptor function. Mol Cell Neurosci (2009) 0.84
Potentiation of synaptic AMPA receptors induced by the deletion of NMDA receptors requires the GluA2 subunit. J Neurophysiol (2010) 0.83
Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One (2009) 0.83
Fasting inhibits the growth and reproductive axes via distinct Y2 and Y4 receptor-mediated pathways. Endocrinology (2007) 0.82
Role of medial prefrontal cortex Narp in the extinction of morphine conditioned place preference. Learn Mem (2013) 0.82
Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target (2009) 0.82
Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice. Eur J Pharmacol (2010) 0.81
Transport of an antifungal trypsin inhibitor isolated from corn across the blood-brain barrier. Antimicrob Agents Chemother (2002) 0.80
Fat grafting as a vehicle for the delivery of recombinant adenoassociated viral vectors to achieve gene modification of muscle flaps. Ann Plast Surg (2013) 0.80
Molecular mechanisms of learning and memory. Expert Rev Mol Med (2003) 0.80
Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study. Free Radic Biol Med (2013) 0.80
HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity. Mol Ther (2008) 0.79
Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake. FASEB J (2011) 0.79
Activity-dependent volume transmission by transgene NPY attenuates glutamate release and LTP in the subiculum. Mol Cell Neurosci (2008) 0.79
Specific knockdown of the D2 long dopamine receptor variant. Neuroreport (2012) 0.79
Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat. J Gene Med (2010) 0.79
Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res (2006) 0.79
Gene therapy for Parkinson's disease. Expert Rev Mol Med (2004) 0.78